Cowen analyst Boris Peaker initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) with a Outperform rating.The analyst comments "MLTX is developing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE